Vericel Corporation (NASDAQ:VCEL) stock rose Tuesday following the company’s announcement of preliminary financial results for the fourth quarter and full year ended December 31, 2025.
The stock is gaining traction as the broader market is experiencing a mixed day, with major indices like the S&P 500 and Nasdaq slightly down.
VCEL Expects $276 Million Revenue in 2025, Profitability Continues
Vericel reported that total net revenue for 2025 is expected to be approximately $276 million, with MACI net revenue of $239.5 million, representing a 23% growth in the fourth quarter. Additionally, the company anticipates achieving GAAP net income profitability for the second consecutive year, supported by a gross margin of 74%.
The company also highlighted significant operational achievements, including the highest number of MACI implants and trained surgeons in any quarter since the product’s launch. With over 900 MACI-trained surgeons and plans to begin commercial manufacturing in a new facility in 2026, Vericel is poised for continued growth.
Vericel ended the period with about $200 million in cash and investments and carries no debt.
The broader market is experiencing a downturn, with the Russell 2000 down 0.22% and the S&P 500 down 0.23%. Despite this, Vericel’s performance stands out, indicating strong company-specific momentum as the stock moves higher.
VCEL Shows Mixed Technical Signals Amid Market Downturn
Vericel is currently trading 1.1% above its 20-day simple moving average (SMA) and 5.3% above its 100-day SMA, demonstrating some short-term strength. However, the stock is trading 0.7% below its 50-day SMA and 1.2% below its 200-day SMA, indicating mixed signals in the longer-term trend.
The stock has decreased by 36.77% over the past 12 months, positioning it closer to its 52-week lows than highs. The current price of $37.66 is significantly below the 52-week high of $63.00, suggesting ongoing challenges despite recent gains.
The RSI is at 45.54, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, the MACD is above its signal line, indicating bullish momentum in the short term.
The combination of neutral RSI and bullish MACD suggests mixed momentum for the stock.
- Key Resistance: $43.00
- Key Support: $35.00
Analysts Set VCEL EPS Forecast at 41 cents for 2026
Investors are looking ahead to the company’s next earnings report, with analysts expecting earnings per share of 41 cents, up from 38 cents in the same quarter last year. Vericel has a consensus Buy rating among analysts with an average price forecast of $57.44, indicating that the stock may be trading at a premium.
EPS Estimate: 41 cents (Up from $0.38 YoY)
Revenue Estimate: $90.92 million (Up from $75.38 million YoY)
Analyst Consensus: Buy Rating ($57.44 Avg Price Forecast)
VCEL Scores Low on Benzinga Edge Momentum
Below is the Benzinga Edge scorecard for Vericel Corporation (VCEL), highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Weak (Score: 7.39/100) — The stock is underperforming relative to the market.
- Quality: Neutral (Score: 55.81/100) — The balance sheet remains stable.
- Value: Risk (Score: 11.04/100) — Trading at a steep premium relative to peers.
The Verdict: Vericel Corporation’s Benzinga Edge signal reveals a challenging environment for the stock. While the Quality score indicates some stability, the low Momentum and Value scores suggest that investors should proceed with caution.
VCEL Price Action: Vericel shares were up 2.92% at $37.66 at the time of publication on Tuesday, according to Benzinga Pro data.
Photo by Piotr Swat via Shutterstock
Recent Comments